For investigators

Information for investigators around trial design, criteria and outcomes.

For more information about the study download our study protocol (PDF 734KB)


SIGNET is a multi-centre, single-blind prospective, group sequential, randomised controlled trial to evaluate the benefits of a single dose of Simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients.

Expression of interest

If you would like to express your interest in your Trust taking part in SIGNET, please complete our Feasibility Questionnaire and send the completed form to

Site set-up documentation

All the documentation you will need to set-up SIGNET at your site:

Download the full document pack (ZIP 8MB)

Download the Site File documentation (ZIP 17MB)

Download the Study Manual (PDF 1.3MB)

For more information about the trial please contact our team at